<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460457</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-I-01</org_study_id>
    <nct_id>NCT03460457</nct_id>
  </id_info>
  <brief_title>Tolerance and Pharmacokinetics of TQB2450</brief_title>
  <official_title>Phase I Study of Tolerance and Pharmacokinetics of TQB2450 Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a
      reasonable regimen for subsequent research.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose(MTD)</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>dose-limiting toxicity(DLT)</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration(Cmax)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak time（Tmax）</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life（t1/2）</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance（CL）</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate(ORR)</measure>
    <time_frame>evaluated in the end of each 3 cycles up to intolerance the toxicity or progression disease (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>TQB2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>Pharmacokinetics/Dynamics Study</description>
    <arm_group_label>TQB2450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced malignancy diagnosed with pathology or cytology who have failed
             standard treatment or no standard treatment;

          -  18-70 years old;Eastern Cooperative Oncology Group performance status:0-1,Life
             expectancy of more than 3 months;

          -  Main organs function is normal;

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 6 months after study is stopped；the result of serum or
             urine pregnancy test should be negative within 7 days prior to study enrollment，and
             the patients required to be non-lactating；Man participants should agree to use and
             utilize an adequate method of contraception throughout treatment and for at least 6
             months after study is stopped;

          -  Patients should be voluntary and sign the informed consents before taking part in the
             study;

        Exclusion Criteria:

          -  Patients who have received programmed cell death protein 1(PD-1) or programmed cell
             death protein ligand(PD-L1) antibody treatment;

          -  Patients who had any&gt; 3 degree immune-related adverse event during any previous
             immunotherapy received;

          -  Appeared severe hypersensitivity after taking other monoclonal antibody drugs;

          -  Other malignancies have been diagnosed in the past 2 years except cured or locally
             curable cancers, such as cutaneous or squamous cell carcinoma, superficial bladder
             cancer, cervical cancer or orthotopic carcinoma of the breast;

          -  Known spinal cord compression, cancer meningitis patients, new onset of central
             nervous system metastasis or stable control of symptoms in patients with brain
             metastases less than 4 weeks; asymptomatic and stable imaging without the need for
             corticosteroid treatment；

          -  Patients with hypothyroidism over 2 degrees;

          -  Patients with active, or who have had, and are likely to relapse, autoimmune diseases;
             the following patients are enrolled: skin disorders without systemic treatment (eg
             vitiligo, psoriasis, hair loss);

          -  Patients treated with glucocorticoids or other immunosuppressive agents within 4 weeks
             prior to dosing;

          -  Interstitial lung disease or non-contagious pneumonia (including past history and
             current illness); uncontrolled systemic diseases including diabetes, hypertension,
             pulmonary fibrosis, acute lung disease, etc. except for radiotherapy-induced
             interstitial pneumonitis;

          -  Serious chronic or active infections require systemic antibacterial, antifungal or
             antiviral treatment (allowing antiviral treatment in patients with hepatocellular
             carcinoma), including tuberculosis infection;

          -  Unstable pleural effusion, pericardial effusion or ascites;

          -  Significant cardiovascular diseases such as heart failure of New York Heart
             Academy(NYHA) Class 2 and above, myocardial infarction within the past 3 months,
             unstable arrhythmias (including QT interval ≥480 ms) or unstable Angina;

          -  Patients with immunodeficiency, including HIV positive or other acquired, congenital
             immunodeficiency disease, or organ transplant history;

          -  Hypertension (systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by
             one medication;

          -  Hepatitis B virus patients with active replication (DNA&gt; 500 cps / mL), hepatitis C;

          -  The first medication interval from the patient: the last chemotherapy for at least 4
             weeks, biological products at least five half-lives;

          -  The first medication interval from the patient: the last chemotherapy for at least 4
             weeks, biological products at least five half-lives;

          -  Inoculated with vaccine or attenuated vaccine within 4 weeks before first
             administration;

          -  Major surgery, or unhealed wounds, ulcers or fractures within 4 weeks prior to the
             first dose;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

